Kiri

Suur-Karja 23 / 15076 Tallinn / 628 2222 / [email protected] / www.kul.ee / Registrikood 70000941

Välisministeerium

[email protected] 09.12.2024 nr 1-12/1424-1

Eelnõu esitamine

Kultuuriministeerium esitab Välisministeeriumile Vabariigi Valitsuse istungile esitamiseks

Vabariigi Valitsuse korralduse „Spordis dopingu kasutamise vastase rahvusvahelise konventsiooni

I lisa muudatuste heakskiitmine“ eelnõu.

Lugupidamisega

(allkirjastatud digitaalselt)

Heidy Purga

minister

Lisad:

1. Eelnõu ühel lehel

2. Seletuskiri viiel lehel

3. I lisa eesti keeles 24-l lehel

4. I lisa inglise keeles 24-l lehel

Kaarel Nestor 628 2260 [email protected]

Siiri Pelisaar 628 2225 [email protected]

WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD

PROHIBITED LIST

2025

This List shall come into effect on 1 January 2025.

2

SUBSTANCES & METHODS PROHIBITED AT ALL TIMES

S0 Non-approved substances.........................................................................................................4 S1 Anabolic agents ...............................................................................................................................5 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. male hypogonadism.

S2 Peptide hormones, growth factors, related substances, and mimetics ...........7 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaemia, male hypogonadism, growth hormone deficiency.

S3 Beta-2 agonists ................................................................................................................................9 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. asthma and other respiratory disorders.

S4 Hormone and metabolic modulators ..................................................................................10 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. breast cancer, diabetes, infertility (female), polycystic ovarian syndrome.

S5 Diuretics and masking agents................................................................................................ 12 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension.

M1 – M2 – M3 Prohibited Methods............................................................................................. 13

SUBSTANCES & METHODS PROHIBITED IN-COMPETITION

S6 Stimulants .......................................................................................................................................... 14 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaphylaxis, attention deficit hyperactivity disorders (ADHD), cold and influenza symptoms.

S7 Narcotics ............................................................................................................................................ 16 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. pain, including from musculoskeletal injuries.

S8 Cannabinoids ................................................................................................................................... 17 S9 Glucocorticoids .............................................................................................................................. 18 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. allergy, anaphylaxis, asthma, inflammatory bowel disease.

SUBSTANCES PROHIBITED IN PARTICULAR SPORTS

P1 Beta-blockers .................................................................................................................................. 19 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension.

INDEX ..................................................................................................................................................................20

TABLE OF CONTENTS Please note that the list of examples of medical conditions below is not inclusive.

3

Introduction The Prohibited List is a mandatory International Standard as part of the World Anti-Doping Program. The List is updated annually following an extensive consultation process facilitated by WADA. The effective date of the List is 01 January 2025. The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. Below are some terms used in this List of Prohibited Substances and Prohibited Methods.

Prohibited In-Competition Subject to a different period having been approved by WADA for a given sport, the In-Competition period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a Competition in which the Athlete is scheduled to participate until the end of the Competition and the Sample collection process.

Prohibited at all times This means that the substance or method is prohibited In- and Out-of-Competition as defined in the Code.

Specified and non-Specified As per Article 4.2.2 of the World Anti-Doping Code, “for purposes of the application of Article 10, all Prohibited Substances shall be Specified Substances except as identified on the Prohibited List. No Prohibited Method shall be a Specified Method unless it is specifically identified as a Specified Method on the Prohibited List”. As per the comment to the article, “the Specified Substances and Methods identified in Article 4.2.2 should not in any way be considered less important or less dangerous than other doping substances or methods. Rather, they are simply substances and methods which are more likely to have been consumed or used by an Athlete for a purpose other than the enhancement of sport performance.”

Substances of Abuse Pursuant to Article 4.2.3 of the Code, Substances of Abuse are substances that are identified as such because they are frequently abused in society outside of the context of sport. The following are designated Substances of Abuse: cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/”ecstasy”), tetrahydrocannabinol (THC).

THE 2025 PROHIBITED LIST WORLD ANTI-DOPING CODE VALID 1 JANUARY 2025

Published by: World Anti-Doping Agency Place Victoria, 800, rue du Square-Victoria, bureau 1700 Montréal (Québec) H3C 0B4 Canada

URL: www.wada-ama.org Tel: +1 514 904 9232 Fax: +1 514 904 8650 E-mail: [email protected]

4

S0

Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

This class covers many different substances including but not limited to BPC-157, 2,4- dinitrophenol (DNP), ryanodine receptor-1-calstabin complex stabilizers [e.g. S-107, S48168 (ARM210)] and troponin activators (e.g. reldesemtiv and tirasemtiv).

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are Specified Substances.

NON-APPROVED SUBSTANCES

5

• 1-Androstenediol (5ɑ-androst-1-ene-3ß, 17ß-diol)

• 1-Androstenedione (5ɑ-androst-1-ene-3, 17-dione)

• 1-Androsterone (3ɑ-hydroxy-5a-androst-1- ene-17-one)

• 1-Epiandrosterone (3ß-hydroxy-5ɑ-androst- 1-ene-17-one)

• 1-Testosterone (17ß-hydroxy-5ɑ-androst-1- en-3-one)

• 4-Androstenediol (androst-4-ene-3ß, 17ß-diol)

• 4-Hydroxytestosterone (4,17ß-dihydroxyandrost-4-en-3-one)

• 5-Androstenedione (androst-5-ene-3,17-dione) • 7ɑ-Hydroxy-DHEA • 7ß-Hydroxy-DHEA • 7-Keto-DHEA • 11ß-Methyl-19-nortestosterone • 17ɑ-Methylepithiostanol (epistane) • 19-Norandrostenediol (estr-4-ene-3,17-diol) • 19-Norandrostenedione (estr-4-ene-3,17-dione) • Androst-4-ene-3,11,17- trione

(11-ketoandrostenedione, adrenosterone) • Androstanolone (5ɑ-dihydrotestosterone,

17ß-hydroxy-5ɑ-androstan-3-one) • Androstenediol (androst-5-ene-3ß,17ß-diol)

• Androstenedione (androst-4-ene-3,17-dione) • Bolasterone • Boldenone • Boldione (androsta-1,4-diene-3,17-dione) • Calusterone • Clostebol • Danazol ([1,2]oxazolo[4’,5’:2,3]pregna-4-en-

20-yn-17ɑ-ol) • Dehydrochlormethyltestosterone (4-chloro-

17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3- one)

• Desoxymethyltestosterone (17ɑ-methyl- 5ɑ-androst-2-en-17ß-ol and 17ɑ-methyl-5ɑ- androst-3-en-17ß-ol)

• Dimethandrolone (7ɑ,11ß-Dimethyl-19- nortestosterone)

• Drostanolone • Epiandrosterone (3ß-hydroxy-5ɑ-androstan-

17-one) • Epi-dihydrotestosterone (17ß-hydroxy-5ß-

androstan-3-one) • Epitestosterone • Ethylestrenol (19-norpregna-4-en-17ɑ-ol) • Fluoxymesterone • Formebolone • Furazabol (17ɑ-methyl [1,2,5]

oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol)

Anabolic agents are prohibited.

When administered exogenously, including but not limited to:

S1.1. ANABOLIC ANDROGENIC STEROIDS (AAS)

S1 ANABOLIC AGENTS

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are non-Specified Substances.

6

S1

• Gestrinone • Mestanolone • Mesterolone • Metandienone (17ß-hydroxy-17ɑ-

methylandrosta-1,4-dien-3-one) • Metenolone • Methandriol • Methasterone (17ß-hydroxy-2ɑ,17ɑ-dimethyl-

5ɑ-androstan-3-one) • Methyl-1-testosterone (17ß-hydroxy-17ɑ-

methyl-5ɑ-androst-1-en-3-one) • Methylclostebol • Methyldienolone (17ß-hydroxy-17ɑ-

methylestra-4,9-dien-3-one) • Methylnortestosterone (17ß-hydroxy-17ɑ-

methylestr-4-en-3-one) • Methyltestosterone • Metribolone (methyltrienolone, 17ß-hydroxy-

17ɑ-methylestra-4,9,11-trien-3-one) • Mibolerone • Nandrolone (19-nortestosterone) • Norboletone

• Norclostebol (4-chloro-17ß-ol-estr-4-en-3-one) • Norethandrolone • Oxabolone • Oxandrolone • Oxymesterone • Oxymetholone • Prasterone (dehydroepiandrosterone, DHEA,

3ß-hydroxyandrost-5-en-17-one) • Prostanozol (17ß-[(tetrahydropyran-2-yl)oxy]-

1’H-pyrazolo[3,4:2,3]-5ɑ-androstane) • Quinbolone • Stanozolol • Stenbolone • Testosterone • Tetrahydrogestrinone (17-hydroxy-18a-

homo-19-nor-17ɑ-pregna-4,9,11-trien-3-one) • Tibolone • Trenbolone (17ß-hydroxyestr-4,9,11-trien-3-

one) • Trestolone (7ɑ-Methyl-19-nortestosterone,

MENT)

and other substances with a similar chemical structure or similar biological effect(s).

S1.1. ANABOLIC ANDROGENIC STEROIDS (AAS) (continued)

S1.2. OTHER ANABOLIC AGENTS

Including, but not limited to:

Clenbuterol, osilodrostat, ractopamine, selective androgen receptor modulators [SARMs, e.g. andarine, enobosarm (ostarine), LGD-4033 (ligandrol), RAD140, S-23 and YK-11], zeranol and zilpaterol.

ANABOLIC AGENTS (continued)

7

S2

Including, but not limited to:

S2.1.1 Erythropoietin receptor agonists, e.g. darbepoetins (dEPO); erythropoietins (EPO); EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide).

S2.1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. cobalt; daprodustat (GSK1278863); IOX2; molidustat (BAY 85-3934); roxadustat (FG-4592); vadadustat (AKB-6548); xenon.

S2.1.3 GATA inhibitors, e.g. K-11706. S2.1.4 Transforming growth factor beta (TGF-ß) signalling inhibitors, e.g. luspatercept;

sotatercept. S2.1.5 Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO).

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited.

S2.1. ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS

PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are non-Specified Substances.

8

Including, but not limited to:

• Fibroblast growth factors (FGFs) • Hepatocyte growth factor (HGF) • Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues • Mechano growth factors (MGFs) • Platelet-derived growth factor (PDGF) • Thymosin-ß4 and its derivatives e.g. TB-500 • Vascular endothelial growth factor (VEGF) and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.

S2.3. GROWTH FACTORS AND GROWTH FACTOR MODULATORS

S2 PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS (continued)

S2.2.1 Testosterone-stimulating peptides in males including, but not limited to: • chorionic gonadotrophin (CG), • luteinizing hormone (LH), • gonadotrophin- releasing hormone (GnRH, gonadorelin) and its agonist analogues

(e.g. buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin), • kisspeptin and its agonist analogues S2.2.2 Corticotrophins and their releasing factors, e.g. corticorelin and tetracosactide S2.2.3 Growth hormone (GH), its analogues and fragments including, but not limited to:

• growth hormone analogues, e.g. lonapegsomatropin, somapacitan and somatrogon • growth hormone fragments, e.g. AOD-9604 and hGH 176-191

S2.2.4 Growth hormone releasing factors, including, but not limited to: • growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293,

CJC-1295, sermorelin and tesamorelin) • growth hormone secretagogues (GHS) and their mimetics [e.g. anamorelin,

capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin and tabimorelin]

• GH-releasing peptides (GHRPs) [e.g. alexamorelin, examorelin (hexarelin), GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5 and GHRP-6]

S2.2. PEPTIDE HORMONES AND THEIR RELEASING FACTORS

9

S3 PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are Specified Substances.

All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to:

• Arformoterol • Fenoterol • Formoterol • Higenamine

• Indacaterol • Levosalbutamol • Olodaterol • Procaterol

• Reproterol • Salbutamol • Salmeterol • Terbutaline

• Tretoquinol (trimetoquinol)

• Tulobuterol • Vilanterol

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above.

NOTE

• Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 600 micrograms over 8 hours starting from any dose;

• Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours in divided doses not to exceed 36 micrograms over 12 hours starting from any dose;

• Inhaled salmeterol: maximum 200 micrograms over 24 hours; • Inhaled vilanterol: maximum 25 micrograms over 24 hours.

EXCEPTIONS

BETA-2 AGONISTS

10

S4

The following hormone and metabolic modulators are prohibited.

Including, but not limited to:

• 2-Androstenol (5ɑ-androst-2-en-17-ol) • 2-Androstenone (5ɑ-androst-2-en-17-one) • 3-Androstenol (5ɑ-androst-3-en-17-ol) • 3-Androstenone (5ɑ-androst-3-en-17-one) • 4-Androstene-3,6,17 trione (6-oxo) • Aminoglutethimide • Anastrozole

• Androsta-1,4,6-triene-3,17-dione (androstatrienedione)

• Androsta-3,5-diene-7,17-dione (arimistane) • Exemestane • Formestane • Letrozole • Testolactone

S4.1. AROMATASE INHIBITORS

Including, but not limited to:

• Bazedoxifene • Clomifene • Cyclofenil

• Elacestrant • Fulvestrant • Ospemifene

• Raloxifene • Tamoxifen • Toremifene

S4.2. ANTI-ESTROGENIC SUBSTANCES [ANTI-ESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)]

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

Prohibited substances in classes S4.1 and S4.2 are Specified Substances. Those in classes S4.3 and S4.4 are non-Specified Substances.

HORMONE AND METABOLIC MODULATORS

11

Including, but not limited to:

• Activin A-neutralizing antibodies • Activin receptor IIB competitors such as: – Decoy activin receptors (e.g. ACE-031) • Anti-activin receptor IIB antibodies

(e.g. bimagrumab)

• Myostatin inhibitors such as: – Agents reducing or ablating myostatin

expression – Myostatin-binding proteins

(e.g. follistatin, myostatin propeptide) – Myostatin- or precursor-neutralizing

antibodies (e.g. apitegromab, domagro- zumab, landogrozumab, stamulumab)

S4.3. AGENTS PREVENTING ACTIVIN RECEPTOR IIB ACTIVATION

S4.4.1

• Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, mitochondrial open reading frame of the 12S rRNA-c (MOTS-c);

• Peroxisome proliferator-activated receptor delta (PPARδ) agonists, e.g. 2-(2-methyl- 4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516) and;

• Rev-erbɑ agonists, e.g. SR9009, SR9011

S4.4.2 Insulins and insulin-mimetics, e.g. S519, S597

S4.4.3 Meldonium

S4.4.4 Trimetazidine

S4.4. METABOLIC MODULATORS

S4 HORMONE AND METABOLIC MODULATORS (continued)

12

S5

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are Specified Substances.

All diuretics and masking agents, including all optical isomers, e.g. d- and l- where relevant, are prohibited.

Including, but not limited to:

• Diuretics such as: Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide;

indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; torasemide; triamterene; xipamide;

• Vaptans, e.g. conivaptan, mozavaptan, tolvaptan; • Plasma expanders by intravenous administration such as: Albumin, dextran, hydroxyethyl starch, mannitol; • Desmopressin; • Probenecid; and other substances with a similar chemical structure or similar biological effect(s).

DIURETICS AND MASKING AGENTS

The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent (except topical ophthalmic administration of a carbonic anhydrase inhibitor or local administration of felypressin in dental anaesthesia), will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent.

NOTE

• Drospirenone; pamabrom; and topical ophthalmic administration of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide);

• Local administration of felypressin in dental anaesthesia.

EXCEPTIONS

13

PROHIBITED METHODS

The following are prohibited: M1.1. The Administration or reintroduction of any quantity of autologous, allogenic

(homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.

M1.2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13); voxelotor and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation.

M1.3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS

The following are prohibited: M2.1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples

collected during Doping Control. Including, but not limited to:

Sample substitution and/or adulteration, e.g. addition of proteases to Sample.

M2.2. Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations.

M2. CHEMICAL AND PHYSICAL MANIPULATION

The following, with the potential to enhance sport performance, are prohibited: M3.1. The use of nucleic acids or nucleic acid analogues that may alter genome

sequences and/or gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies.

M3.2. The use of normal or genetically modified cells.

M3. GENE AND CELL DOPING

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited methods in this class are non-Specified except methods in M2.2. which are Specified Methods.

Donation of blood or blood components, including by apheresis, is not prohibited when performed in a collection center accredited by the relevant regulatory authority of the country in which it operates.

NOTE

14

S6

All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited.

A stimulant not expressly listed in this section is a Specified Substance.

PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances except those in S6.A, which are non-Specified Substances. Substances of Abuse in this section: cocaine and methylenedioxymethamphetamine (MDMA / “ecstasy”)

Stimulants include:

• Adrafinil • Amfepramone • Amfetamine • Amfetaminil • Amiphenazole • Benfluorex • Benzylpiperazine • Bromantan • Clobenzorex • Cocaine • Cropropamide • Crotetamide • Fencamine • Fenetylline • Fenfluramine • Fenproporex

• Fonturacetam [4-phenylpiracetam (carphedon)]

• Furfenorex • Hydrafinil (fluorenol) • Lisdexamfetamine • Mefenorex • Mephentermine • Mesocarb • Metamfetamine(d-) • p-methylamfetamine • Modafinil • Norfenfluramine • Phendimetrazine • Phentermine • Prenylamine • Prolintane

S6.A: NON-SPECIFIED STIMULANTS

STIMULANTS

15

S6

Including, but not limited to:

• 2-phenylpropan-1-amine (ß-methylphenylethyl- amine, BMPEA)

• 3-Methylhexan-2-amine (1,2-dimethylpentylamine)

• 4-Fluoromethylphenidate • 4-Methylhexan-2-amine

(1,3-dimethylamylamine, 1,3 DMAA, methylhexanea- mine)

• 4-Methylpentan-2-amine (1,3-dimethylbutylamine)

• 5-Methylhexan-2-amine (1,4-dimethylamylamine, 1,4-dimethylpentylamine, 1,4-DMAA)

• Benzfetamine • Cathine** • Cathinone and its ana-

logues, e.g. mephedrone, methedrone, and ɑ - pyrrolidinovalerophenone

• Dimetamfetamine (dimethylamphetamine)

• Ephedrine***

• Epinephrine**** (adrenaline)

• Etamivan • Ethylphenidate • Etilamfetamine • Etilefrine • Famprofazone • Fenbutrazate • Fencamfamin • Heptaminol • Hydroxyamfetamine

(parahydroxyamphet- amine)

• Isometheptene • Levmetamfetamine • Meclofenoxate • Methylenedioxymetham-

phetamine • Methylephedrine*** • Methylnaphthidate

[(±)-methyl-2-(naphthalen-2- yl)-2-(piperidin-2-yl)acetate]

• Methylphenidate • Midodrine

• Nikethamide • Norfenefrine • Octodrine (1,5-dimethyl-

hexylamine) • Octopamine • Oxilofrine

(methylsynephrine) • Pemoline • Pentetrazol • Phenethylamine

and its derivatives • Phenmetrazine • Phenpromethamine • Propylhexedrine • Pseudoephedrine***** • Selegiline • Sibutramine • Solriamfetol • Strychnine • Tenamfetamine

(methylenedioxyamphet- amine)

• Tesofensine • Tuaminoheptane

* Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2025 Monitoring Program and are not considered Prohibited Substances.

** Cathine (d-norpseudoephedrine) and its l-isomer: Prohibited when its concentration in urine is greater than 5 micrograms per millilitre. *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per millilitre. **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local

anaesthetic agents. ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per millilitre.

S6.B: SPECIFIED STIMULANTS

• Clonidine, guanfacine; • Imidazoline derivatives for dermatological, nasal, ophthalmic or otic use (e.g. brimonidine,

clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline, tetryzoline, tramazoline, xylometazoline) and those stimulants included in the 2025 Monitoring Program*.

and other substances with a similar chemical structure or similar biological effect(s).

STIMULANTS (continued)

EXCEPTIONS

16

S7

• Buprenorphine • Dextromoramide • Diamorphine

(heroin)

• Fentanyl and its derivatives

• Hydromorphone • Methadone

• Morphine • Nicomorphine • Oxycodone • Oxymorphone

• Pentazocine • Pethidine • Tramadol

The following narcotics, including all optical isomers, e.g. d- and l- where relevant, are prohibited.

PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. Substance of Abuse in this section: diamorphine (heroin)

NARCOTICS

17

S8

All natural and synthetic cannabinoids are prohibited, e.g.

• In cannabis (hashish, marijuana) and cannabis products • Natural and synthetic tetrahydrocannabinols (THCs) • Synthetic cannabinoids that mimic the effects of THC

PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. Substance of Abuse in this section: tetrahydrocannabinol (THC)

• Cannabidiol

CANNABINOIDS

EXCEPTIONS

18

S9

All glucocorticoids are prohibited when administered by any injectable, oral [including oromucosal (e.g. buccal, gingival, sublingual)] or rectal route.

Including, but not limited to:

• Beclometasone • Betamethasone • Budesonide • Ciclesonide • Cortisone • Deflazacort

• Dexamethasone • Flunisolide • Fluocortolone • Fluticasone • Hydrocortisone • Methylprednisolone

• Mometasone • Prednisolone • Prednisone • Triamcinolone acetonide

PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances.

GLUCOCORTICOIDS

• Other routes of administration (including inhaled, and topical: dental-intracanal, dermal, intranasal, ophthalmological, otic and perianal) are not prohibited when used within the manufacturer’s licensed doses and therapeutic indications.

NOTE

19

P1

Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated (*). • Archery (WA)* • Automobile (FIA) • Billiards (all disciplines) (WCBS) • Darts (WDF) • Golf (IGF) • Mini-Golf (WMF) • Shooting (ISSF, IPC)*

• Underwater sports (CMAS)* in all subdisciplines of freediving, spearfishing and target shooting

Including, but not limited to: • Acebutolol • Alprenolol • Atenolol • Betaxolol • Bisoprolol

• Bunolol • Carteolol • Carvedilol • Celiprolol • Esmolol

• Labetalol • Metipranolol • Metoprolol • Nadolol • Nebivolol

• Oxprenolol • Pindolol • Propranolol • Sotalol • Timolol

*Also prohibited Out-of-Competition

PROHIBITED IN PARTICULAR SPORTS All prohibited substances in this class are Specified Substances.

BETA-BLOCKERS

20

INDEX (±)-Methyl-2-(naphthalen-2-yl)-2- (piperidin-2-yl)acetate, 15

1-Androstenediol, 5

1-Androstenedione, 5

1-Androsterone, 5

1-Epiandrosterone, 5

1-Testosterone, 5

1,2-Dimethylpentylamine, 15

[1,2]Oxazolo[4’,5’:2,3]pregna-4-en-20- yn-17ɑ-ol), 5

1,3-Dimethylamylamine (1,3 DMAA), 15

1,3-Dimethylbutylamine, 15

1,4-Dimethylamylamine (1,4-DMAA), 15

1,4-Dimethylpentylamine, 15

1,5- Dimethyl-hexylamine, 15

2-Androstenol, 10

2-Androstenone, 10

2-Phenylpropan-1-amine, 15

2,4-Dinitrophenol (DNP), 4

3ɑ-Hydroxy-5ɑ-androst-1-ene-17-one, 5

3ß-Hydroxy-5ɑ-androst-1-ene-17-one, 5

3ß-Hydroxy-5ɑ-androstan-17-one, 5

3ß-Hydroxyandrost-5-en-17-one, 6

3-Androstenol, 10

3-Androstenone, 10

3-Methylhexan-2-amine, 15

4-Androstene-3,6,17 trione, 10

4-Androstenediol, 5

4-Chloro-17ß-hydroxy-17ɑ- methylandrosta-1,4-dien-3-one, 5

4-Chloro-17ß-ol-estr-4-en-3-one, 6

4-Fluoromethylphenidate, 15

4-Hydroxytestosterone, 5

4-Methylhexan-2-amine, 15

4-Methylpentan-2-amine, 15

4-Phenylpiracetam, 14

4,17ß-Dihydroxyandrost-4-en-3-one, 5

5ɑ-Androst-1-ene-3, 17-dione, 5

5ɑ-Androst-1-ene-3ß, 17ß-diol, 5

5ɑ-Androst-2-en-17-ol, 10

5ɑ-Androst-2-en-17-one, 10

5ɑ-Androst-3-en-17-ol, 10

5ɑ-Androst-3-en-17-one, 10

5ɑ-Dihydrotestosterone, 5

5-Androstenedione, 5

5-Methylhexan-2-amine, 15

6-Oxo, 10

7ɑ-Hydroxy-DHEA, 5

7ɑ,11ß-Dimethyl-19-nortestosterone, 5

7ɑ-Methyl-19-nortestosterone, 6

7ß-Hydroxy-DHEA, 5

7-Keto-DHEA, 5

11ß-Methyl-19-nortestosterone, 5

11-Ketoandrostenedione, 5

17ɑ-Methyl [1,2,5]oxadiazolo[3’,4’:2,3]- 5ɑ-androstan-17ß-ol, 5

17ɑ-Methyl-5ɑ-androst-2-en-17ß-ol, 5

17ɑ-Methyl-5ɑ-androst-3-en-17ß-ol, 5

17ɑ-Methylepithiostanol, 5

17ß-Hydroxy-2ɑ,17ɑ-dimethyl-5ɑ- androstan-3-one, 6

17ß-Hydroxy-5ɑ-androst-1-en-3-one, 5

17ß-Hydroxy-5ɑ-androstan-3-one, 5

17ß-Hydroxy-5ß-androstan-3-one, 5

17ß-hydroxy-17ɑ-methyl-5ɑ-androst-1- en-3-one, 6

17ß-Hydroxy-17ɑ-methylandrosta-1,4- dien-3-one, 6

17ß-Hydroxy-17ɑ-methylestr-4-en-3- one, 6

17ß-Hydroxy-17ɑ-methylestra-4,9-dien- 3-one, 6

17ß-Hydroxy-17ɑ-methylestra-4,9,11- trien-3-one, 6

17ß-Hydroxyestr-4,9,11-trien-3-one, 6

17ß-[(Tetrahydropyran-2-yl)oxy]-1’H- pyrazolo[3,4:2,3]-5ɑ-androstane, 6

17-Hydroxy-18a-homo-19-nor-17ɑ- pregna-4,9,11-trien-3-one, 6

19-Norandrostenediol, 5

19-Norandrostenedione, 5

19-Norpregna-4-en-17ɑ-ol, 5

19-Nortestosterone, 6

ɑ-Pyrrolidinovalerophenone, 15

ß-Methylphenylethylamine, 15

A ACE-031, 11

Acebutolol, 19

Acetazolamide, 12

Activators of the AMP-activated protein kinase (AMPK), 11

Activin A-neutralizing antibodies, 11

Activin receptor IIB competitors, 11

Adrafinil, 14

Adrenaline, 15

Adrenosterone, 5

AICAR, 11

Albumin, 12

Alexamorelin, 8

Alprenolol, 19

Amfepramone, 14

Amfetamine, 14

Amfetaminil, 14

Amiloride, 12

Aminoglutethimide, 10

Amiphenazole, 14

AMP-activated protein kinase (AMPK), 11

Anamorelin, 8

Anastrozole, 10

Andarine, 6

Androst-4-ene-3ß,17ß-diol, 5

Androst-4-ene-3,11,17- trione, 5

Androst-4-ene-3,17-dione, 5

Androst-5-ene-3ß,17ß-diol, 5

Androst-5-ene-3,17-dione, 5

Androsta-1,4,6-triene-3,17-dione, 10

Androsta-1,4-diene-3,17-dione, 5

Androsta-3,5-diene-7,17-dione, 10

Androstanolone, 5

Androstatrienedione, 10

Androstenediol, 5

Androstenedione, 5

Anti-activin receptor IIB antibodies, 11

AOD-9604, 8

Apheresis, 13

Apitegromab, 11

Arformoterol, 9

Arimistane, 10

ARM210, 4

Asialo EPO, 7

Atenolol, 19

B Bazedoxifene, 10

Beclometasone, 18

Bendroflumethiazide, 12

Benfluorex, 14

Benzfetamine, 15

Benzylpiperazine, 14

Betamethasone, 18

Betaxolol, 19

Bimagrumab, 11

Bisoprolol, 19

Blood, 13

Blood (autologous), 13

Blood (components), 13

Blood (heterologous), 13

Blood (homologous), 13

Blood manipulation, 13

BMPEA, 15

Bolasterone, 5

21

INDEX Boldenone, 5

Boldione, 5

BPC-157, 4

Brimonidine, 15

Brinzolamide, 12

Bromantan, 14

Budesonide, 18

Bumetanide, 12

Bunolol, 19

Buprenorphine, 16

Bupropion, 15

Buserelin, 8

C Caffeine, 15

Calusterone, 5

Cannabidiol, 17

Cannabis, 17

Canrenone, 12

Capromorelin, 8

Carbamylated EPO (CEPO), 7

Carphedon, 14

Carteolol, 19

Carvedilol, 19

Cathine, 12, 15

Cathinone, 15

Celiprolol, 19

Cell (doping), 13

Cell (genetically modified), 13

Cell (normal), 13

Cell (red blood), 13

Chlorothiazide, 12

Chlortalidone, 12

Chorionic Gonadotrophin (CG), 8

Ciclesonide, 18

CJC-1293, 8

CJC-1295, 8

Clenbuterol, 6

Clobenzorex, 14

Clomifene, 10

Clonazoline, 15

Clonidine, 15

Clostebol, 5

CNTO-530, 7

Cobalt, 7

Cocaine, 14

Conivaptan, 12

Corticorelin, 8

Corticotrophins, 8

Cortisone, 18

Cropropamide, 14

Crotetamide, 14

Cyclofenil, 10

D Danazol, 5

Daprodustat, 7

Darbepoetins (dEPO), 7

Deflazacort, 18

Dehydrochlormethyltestosterone, 5

Dehydroepiandrosterone (DHEA), 6

Deslorelin, 8

Desmopressin, 12

Desoxymethyltestosterone, 5

Dexamethasone, 18

Dextran, 12

Dextromoramide, 16

Diamorphine, 16

Dimetamfetamine, 15

Dimethandrolone, 5

Dimethylamphetamine, 15

Domagrozumab, 11

Dorzolamide, 12

Drospirenone, 12

Drostanolone, 5

E Ecstasy, 14

Efaproxiral (RSR13), 13

Elacestrant, 10

Enobosarm, 6

Ephedrine, 12, 15

Epiandrosterone, 5

Epi-dihydrotestosterone, 5

Epinephrine, 15

Epistane, 5

Epitestosterone, 5

EPO-based constructs, 7

EPO-Fc, 7

EPO-mimetic agents, 7

Erythropoietin receptor agonists, 7

Erythropoietins (EPO), 7

Esmolol, 19

Estr-4-ene-3,17-diol, 5

Estr-4-ene-3,17-dione, 5

Etacrynic acid, 12

Etamivan, 15

Ethylestrenol, 5

Ethylphenidate, 15

Etilamfetamine, 15

Etilefrine, 15

Examorelin, 8

Exemestane, 10

F Famprofazone, 15

Felypressin, 12

Fenbutrazate, 15

Fencamfamin, 15

Fencamine, 14

Fenetylline, 14

Fenfluramine, 14

Fenoterol, 9

Fenoxazoline, 15

Fenproporex, 14

Fentanyl, 16

Fibroblast growth factors (FGFs), 8

Flunisolide, 18

Fluocortolone, 18

Fluorenol, 14

Fluoxymesterone, 5

Fluticasone, 18

Follistatin, 11

Fonturacetam, 14

Formebolone, 5

Formestane, 10

Formoterol, 9, 12

Fulvestrant, 10

Furazabol, 5

Furfenorex, 14

Furosemide, 12

G GATA inhibitors, 7

Gene doping, 13

Gene editing, 13

Gene silencing, 13

Gene transfer, 13

Gestrinone, 6

Ghrelin, 8

GH-releasing peptides (GHRPs), 8

Gonadorelin, 8

Gonadotrophin-releasing hormone (GnRH), 8

Goserelin, 8

Growth hormone (GH), 8

Growth hormone secretagogues (GHS), 8

Guanfacine, 15

GW1516, 11

GW501516, 11

22

INDEX H Haemoglobin (products), 13

Haemoglobin (based blood substitutes), 13

Haemoglobin (microencapsulated products), 13

Hashish, 17

Hepatocyte growth factor (HGF), 8

Heptaminol, 15

Heroin, 16

Hexarelin, 8

hGH 176-191, 8

Higenamine, 9

Histrelin, 8

Hydrafinil, 14

Hydrochlorothiazide, 12

Hydrocortisone, 18

Hydromorphone, 16

Hydroxyamfetamine, 15

Hydroxyethyl starch, 12

Hypoxia-inducible factor (HIF) activating agents, 7

I Ibutamoren, 8

Imidazoline, 15

Indacaterol, 9

Indanazoline, 15

Indapamide, 12

Infusions, 13

Injections (>100 mL), 13

Innate repair receptor agonists, 7

Insulin-like growth factor-1 (IGF-1), 8

Insulin-mimetics, 11

Insulins, 11

Intravenous infusions/injections, 13

IOX2, 7

Ipamorelin, 8

Isometheptene, 15

K K-11706, 7

Kisspeptin, 8

L Labetalol, 19

Landogrozumab, 11

Lenomorelin, 8

Letrozole, 10

Leuprorelin, 8

Levmetamfetamine, 15

Levosalbutamol, 9

LGD-4033, 6

Ligandrol, 6

Lisdexamfetamine, 14

Lonapegsomatropin, 8

Luspatercept, 7

Luteinizing hormone (LH), 8

M Macimorelin, 8

Mannitol, 12

Marijuana, 17

Mecasermin, 8

Mechano growth factors (MGFs), 8

Meclofenoxate, 15

Mefenorex, 14

Meldonium, 11

MENT, 6

Mephedrone, 15

Mephentermine, 14

Mesocarb, 14

Mestanolone, 6

Mesterolone, 6

Metamfetamine(d-), 14

Metandienone, 6

Metenolone, 6

Methadone, 16

Methandriol, 6

Methasterone, 6

Methedrone, 15

Methoxy polyethylene glycol-epoetin beta (CERA), 7

Methyl-1-testosterone, 6

Methylclostebol, 6

Methyldienolone, 6

Methylenedioxyamphetamine, 15

Methylenedioxymethamphetamine, 15

Methylephedrine, 12, 15

Methylhexaneamine, 15

Methylnaphtidate, 15

Methylnortestosterone, 6

Methylphenidate, 15

Methylprednisolone, 18

Methylsynephrine, 15

Methyltestosterone, 6

Methyltrienolone, 6

Metipranolol, 19

Metolazone, 12

Metoprolol, 19

Metribolone, 6

Mibolerone, 6

Midodrine, 15

Mitochondrial open reading frame of the 12S rRNA-c, 11

MK-677, 8

Modafinil, 14

Molidustat, 7

Mometasone, 18

Morphine, 16

MOTS-c, 11

Mozavaptan, 12

Myostatin inhibitors, 11

Myostatin precursor-neutralizing antibodies, 11

Myostatin propeptide, 11

Myostatin-binding proteins, 11

Myostatin-neutralizing antibodies, 11

N Nadolol, 19

Nafarelin, 8

Nandrolone, 6

Naphazoline, 15

Nebivolol, 19

Nicomorphine, 16

Nicotine, 15

Nikethamide, 15

Norboletone, 6

Norclostebol, 6

Norethandrolone, 6

Norfenefrine, 15

Norfenfluramine, 14

Nucleic acids, 13

Nucleic acid analogues, 13

O Octodrine, 15

Octopamine, 15

Olodaterol, 9

Osilodrostat, 6

Ospemifene, 10

Ostarine, 6

Oxabolone, 6

Oxandrolone, 6

Oxilofrine, 15

Oxprenolol, 19

Oxycodone, 16

Oxymesterone, 6

Oxymetazoline, 15

Oxymetholone, 6

Oxymorphone, 16

23

INDEX P Pamabrom, 12

Parahydroxyamphetamine, 15

Peginesatide, 7

Pemoline, 15

Pentazocine, 16

Pentetrazol, 15

Perfluorochemicals, 13

Peroxisome proliferator activated receptor delta agonists, 11

Pethidine, 16

Phendimetrazine, 14

Phenethylamine, 15

Phenmetrazine, 15

Phenpromethamine, 15

Phentermine, 14

Phenylephrine, 15

Phenylpropanolamine, 15

Pindolol, 19

Pipradrol, 15

Plasma expanders, 12

Platelet-derived growth factor (PDGF), 8

p-methylamfetamine, 14

Pralmorelin, 8

Prasterone, 6

Prednisolone, 18

Prednisone, 18

Prenylamine, 14

Probenecid, 12

Procaterol, 9

Prolintane, 14

Propranolol, 19

Propylhexedrine, 15

Prostanozol, 6

Proteases, 13

Pseudoephedrine, 12, 15

Q Quinbolone, 6

R RAD140, 6

Ractopamine, 6

Raloxifene, 10

Reldesemtiv, 4

Reproterol, 9

Rev-erbɑ agonists, 11

Roxadustat, 7

Ryanodine receptor-1-calstabin

complex stabilizers, 4

S S-107, 4

S-23, 6

S48168, 4

S519, 11

S597, 11

Salbutamol, 9, 12

Salmeterol, 9

Selective androgen receptor modulators (SARMs), 6

Selegiline, 15

Sermorelin, 8

Sibutramine, 15

Solriamfetol, 15

Somapacitan, 8

Somatrogon, 8

Sotalol, 19

Sotatercept, 7

Spironolactone, 12

SR9009, 11

SR9011, 11

Stamulumab, 11

Stanozolol, 6

Stenbolone, 6

Strychnine, 15

Synephrine, 15

T Tabimorelin, 8

Tamoxifen, 10

Tampering, 13

TB-500, 8

Tenamfetamine, 15

Terbutaline, 9

Tesamorelin, 8

Tesofensine, 15

Testolactone, 10

Testosterone, 6

Testosterone-stimulating peptides 8

Tetracosactide, 8

Tetrahydrocannabinols, 17

Tetrahydrogestrinone, 6

Tetryzoline, 15

Thiazides, 12

Thymosin-ß4, 8

Tibolone, 6

Timolol, 19

Tirasemtiv, 4

Tolvaptan, 12

Torasemide, 12

Toremifene, 10

Tramadol, 16

Tramazoline, 15

Transforming growth factor beta (TGF-ß) signalling inhibitors, 7

Trenbolone, 6

Trestolone, 6

Tretoquinol, 9

Triamcinolone acetonide, 18

Triamterene, 12

Trimetazidine, 11

Trimetoquinol, 9

Triptorelin, 8

Troponin activators, 4

Tuaminoheptane, 15

Tulobuterol, 9

V Vadadustat (AKB-6548), 7

Vaptans, 12

Vascular endothelial growth factor (VEGF), 8

Vilanterol, 9

Voxelotor, 13

X Xenon, 7

Xipamide, 12

Xylometazoline, 15

Y YK-11, 6

Z Zeranol, 6

Zilpaterol, 6

www.wada-ama.org

www.wada-ama.org

Islandi väljak 1 / 15049 Tallinn / +372 637 7000 / [email protected] / www.vm.ee / Registrikood 70002526

Vabariigi Valitsus

Stenbocki maja

Rahukohtu 3

15161 Tallinn

14.01.2025 nr 15.1-3/7436-6

Välisministeerium esitab Kultuuriministeeriumi ettepanekul Vabariigi Valitsuse istungi

päevakorda Vabariigi Valitsuse korralduse „Spordis dopingu kasutamise vastase rahvusvahelise

konventsiooni I lisa muudatuste heakskiitmine“ eelnõu.

Lugupidamisega

(allkirjastatud digitaalselt)

Margus Tsahkna

minister

Lisad: 1) korralduse eelnõu 1 lehel

2) seletuskiri 5 lehel

3) leping eesti keeles 24 lehel

4) leping inglise keeles 24 lehel

5) Kultuuriministeeriumi esituskiri 1 lehel

Stina-Maria Lusti, 637 7426

[email protected]